Lotus Eye Hospital and Institute Limited

Informe acción NSEI:LOTUSEYE

Capitalización de mercado: ₹1.7b

Lotus Eye Hospital and Institute Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Lotus Eye Hospital and Institute ha aumentado sus beneficios a una tasa media anual de 31.6%, mientras que los beneficios de la industria de Healthcare han experimentado un crecimiento de 31.6% anual. Los ingresos han ido creciendo a una tasa media de 6.4% al año. La rentabilidad financiera de Lotus Eye Hospital and Institute es de 4.9%, y sus márgenes netos son de 6%.

Información clave

26.8%

Tasa de crecimiento de los beneficios

27.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare 29.4%
Tasa de crecimiento de los ingresos7.0%
Rentabilidad financiera3.6%
Margen neto4.4%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Desglose de ingresos y gastos

Cómo gana y gasta dinero Lotus Eye Hospital and Institute. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NSEI:LOTUSEYE Ingresos, gastos y beneficios (INR Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 2448522350
31 Mar 2448229350
31 Dec 2348535340
30 Sep 2348640340
30 Jun 234774100
31 Mar 2347041340
31 Dec 2246440310
30 Sep 2245942310
30 Jun 224494600
31 Mar 2238930320
31 Dec 2138936230
30 Sep 2137232230
30 Jun 213352000
31 Mar 2132416230
31 Dec 20300-5360
30 Sep 20301-14360
30 Jun 20335-600
31 Mar 2040611360
31 Dec 1942021300
30 Sep 1941520300
30 Jun 194011100
31 Mar 193847350
31 Dec 183827320
30 Sep 183819320
30 Jun 183841400
31 Mar 1838017310
31 Dec 173738290
30 Sep 173594290
30 Jun 17350600
31 Mar 173404290
31 Dec 163307270
30 Sep 163247270
30 Jun 16314000
31 Mar 163111270
31 Dec 15311-5510
30 Sep 15315-6510
30 Jun 15308-14510
31 Mar 15302-20310
31 Dec 14298-12410
30 Sep 14290-9410
30 Jun 142891410
31 Mar 142880410
31 Dec 132874370
30 Sep 132852370

Ingresos de calidad: LOTUSEYE tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(7.3%) de LOTUSEYE son inferiores a los del año pasado (8.6%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lLOTUSEYE han crecido significativamente en un 35.2% al año.

Acelerando crecimiento: LOTUSEYE ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: LOTUSEYE tuvo un crecimiento negativo de los beneficios (-10.9%) durante el año pasado, lo que dificulta la comparación con la media de la industria Healthcare (29.5%).


Rentabilidad financiera

Alta ROE: La rentabilidad financiera de LOTUSEYE (6%) se considera baja.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado